Antipsychotic medications and dental caries in newly diagnosed schizophrenia: A nationwide cohort study

Psychiatry Research

Volumn 245, Issue , 2016, Pages 45-50

  Hu, Kai Fang ^a,b   Chou, Yu Hsiang ^b   Wen, Yen Hsia ^a   Hsieh, Kun Pin ^a   Tsai, Jui Hsiu ^a   Yang, Pinchen ^b   Yang, Yi Hsin ^a   Lin, Chun Hung Richard ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Dental caries; Hypersalivation; Hyposalivation; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATENOLOL; BIPERIDEN; CARTEOLOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIPHENHYDRAMINE; ENALAPRIL MALEATE; FLUPENTIXOL; FUROSEMIDE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ADULT; ARTICLE; COHORT ANALYSIS; DENTAL CARIES; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; HYPERSALIVATION; HYPOSALIVATION; INCOME; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; TREATMENT DURATION; CHEMICALLY INDUCED; COMPLICATION; INCIDENCE; MIDDLE AGED; PROTECTION; STATISTICAL MODEL; TAIWAN; XEROSTOMIA;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DENTAL CARIES; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTECTIVE FACTORS; RISK FACTORS; SCHIZOPHRENIA; TAIWAN; XEROSTOMIA;

EID: 84981513528     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.07.047     Document Type: Article

References (34)

1. Amerongen, A.V., Veerman, E.C., Saliva – the defender of the oral cavity. Oral. Dis. 8 (2002), 12–22.
2. Arnaiz, A., Zumárraga, M., Díez-Altuna, I., Uriarte, J.J., Moro, J., Pérez-Ansorena, M.A., Oral health and the symptoms of schizophrenia. Psychiatry Res. 188 (2011), 24–28.
3. Atkinson, J.C., Fox, P.C., Salivary gland dysfunction. Clin. Geriatr. Med. 8 (1992), 499–511.
4. Buchanan, R.W., Carpenter, W.T., Concept of schizophrenia. Sadock, B.J., Sadock, V.A., (eds.), 8th ed., Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 1, 2005, Lippincott Williams & Wilkins, Baltimore, 1329.
5. Cheng, T.M., Taiwan's National Health Insurance system: high value for the dollar. Okma, K.G.H., Crivelli, L., (eds.) Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan, 2009, World Scientific, New Jersey, 71–204.
6. Chu, K.Y., Yang, N.P., Chou, P., Chiu, H.J., Chi, L.Y., Factors associated with dental caries among institutionalized residents with schizophrenia in Taiwan: across-sectional study. BMC Public Health, 10, 2010, 482.
7. Chu, K.Y., Yang, N.P., Chou, P., Chiu, H.J., Chi, L.Y., Comparison of oral health between inpatients with schizophrenia and disabled people or the general population. J. Formos. Med. Assoc. 111 (2012), 214–219.
8. Dai, J., Li, Z., Rocke, D., 2006. Hieratchical Logistic Regression Modeling with SAS GLIMMIX. 〈http://www.lexjansen.com/wuss/2006/Analytics/ANL-Dai.pdf〉.
9. Dukić, W., Dobrijević, T.T., Katunarić, M., Lesić, S., Caries prevalence in chronic alcoholics and the relationship to salivary flow rate and pH. Cent. Eur. J. Public Health 21 (2013), 43–47.
10. Dumitrescu, A.L., Dogaru, C.B., Dogaru, C.D., Instability of self-esteem and affective lability as determinants of self-reported oral health status and oral health-related behaviors. J. Contemp. Dent. Pract. 9 (2008), 38–45.
11. Freedman, R., Schizophrenia. N. Engl. J. Med. 349 (2003), 1738–1749.
12. Friedlander, A.H., Liberman, R.P., Oral health care for the patients with schizophrenia. Spec. Care Dent. 11 (1991), 179–183.
13. Friedlander, A.H., Marder, S.R., The psychopathology, medical management and dental implications of schizophrenia. J. Am. Dent. Assoc. 133 (2002), 603–610.
14. Hashimoto, Y., Uno, J., Miwa, T., Kurihara, M., Tanifuji, H., Tensho, M., Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin. Neurosci. 66 (2012), 405–510.
15. Kenkre, A.M., Spadigam, A.E., Oral health and treatment needs in institutionalized psychiatric patients in India. Indian J. Dent. Res. 11 (2000), 5–11.
16. Kisely, S., Baghaie, H., Lalloo, R., Siskind, D., Johnson, N.W., A systematic review and meta-analysis of the association between poor oral health and severe mental illness. Psychosom. Med 77 (2015), 83–92.
17. Kossioni, A.E., Kossionis, G.E., Polychronopoulou, A., Oral health status of elderly hospitalised psychiatric patients. Gerodontology 29 (2012), 272–283.
18. Morales-Chávez, M.C., Rueda-Delgado, Y.M., Peña-Orozco, D.A., Prevalence of bucco-dental pathologies in patients with schizophrenic disorders. J. Clin. Exp. Dent. 6 (2014), e7–e11.
19. Muench, J., Hamer, A.M., Adverse effects of antipsychotic medications. Am. Fam. Physician 81 (2010), 617–622.
20. Nederfors, T., Dahlöf, C., Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population. Eur. J. Oral. Sci. 104 (1966), 262–268.
21. Oglodek, E.A., Szota, A., Just, M., Mos, D., Araszkiewicz, A., Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. Pharmacol. Rep. 66 (2014), 920–926.
22. Oglodek, E., Szota, A., Just, M., Mos, D., Araszkiewicz, A., The role of the neuroendocrine and immune systems in the pathogenesis of depression. Pharmacol. Rep. 66 (2014), 776–781.
23. Pihlstrom, B.L., Michalowicz, B.S., Johnson, N.W., Periodontal diseases. Lancet 366 (2005), 1809–1820.
24. Pope, J.E., Curzon, M.E., The dental status of cerebral palsied children. Pediatr. Dent. 13 (1991), 156–162.
25. Ramon, T., Grinshpoon, A., Zusman, S.P., Weizman, A., Oral health and treatment needs of institutionalized chronic psychiatric patients in Israel. Eur. Psychiatry 18 (2003), 101–105.
26. Rodrigues dos Santos, M.T., Masiero, D., Novo, N.F., Simionato, M.R., Oral conditions in children with cerebral palsy. J. Dent. Child. 70 (2003), 40–46.
27. Saleh, J., Figueiredo, M.A., Cherubini, K., Salum, F.G., Salivary hypofunction: an update on aetiology, diagnosis and therapeutics. Arch. Oral Biol. 60 (2015), 242–255.
28. Scully, C., Bagan, J.V., Adverse drug reactions in the orofacial region. Crit. Rev. Oral Biol. Med. 15 (2004), 221–239.
29. Sekine, Y., Rikihisa, T., Ogata, H., Echizen, H., Arakawa, Y., Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur. J. Clin. Pharmacol. 55 (1999), 583–587.
30. Selwitz, R.H., Ismail, A.I., Pitts, N.B., Dental caries. Lancet 369 (2007), 51–59.
31. Tahmassebi, F., Curzon, M.E., Prevalence of drooling in children with cerebral palsy attending special schools. Dev. Med. Child Neurol. 45 (2003), 613–617.
32. Tani, H., Uchida, H., Suzuki, T., Shibuya, Y., Shimanuki, H., Watanabe, K., Den, R., Nishimoto, M., Hirano, J., Takeuchi, H., Nio, S., Nakajima, S., Kitahata, R., Tsuboi, T., Tsunoda, K., Kikuchi, T., Mimura, M., Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. BMC Oral Health, 12, 2012, 32.
33. Vinayak, V., Annigeri, R.G., Patel, H.A., Mittal, S., Adverse affects of drugs on saliva and salivary glands. J. Orofac. Sci. 5 (2013), 15–20.
34. Zusman, S.P., Ponizovsky, A.M., Dekel, D., Masarwa, A.E., Ramon, T., Natapov, L., Grinshpoon, A., An assessment of the dental health of chronic institutionalized patients with psychiatric disease in Israel. Spec. Care Dent. 30 (2010), 18–22.